Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.595 +0.225 (+2.40%)
Streaming Delayed Price Updated: 1:16 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value. 
Via Talk Markets
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace
7 Low P/E Stocks Poised to Rebound
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. 
Via InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Recap: Viatris Q3 Earnings
Via Benzinga
2 Top Value Stocks to Buy in October
These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects. 
Via The Motley Fool
Viatris Stock: Bear vs. Bull
This is a case where both sides have compelling arguments. 
Via The Motley Fool
3 Large-Cap Stocks to Buy Trading Below Book Value
There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Viatris now faces a narrower path to commercializing a generic copy of Ozempic. 
Via The Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
There's a chance shareholders won't notice any difference. 
Via The Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
These stocks may not be for everyone, but income-seekers might find what they're looking for in them. 
Via The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Where Will Viatris Be in 5 Years?
Can this become a good growth business to invest in? 
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy
These two stocks look like bargains right now for income investors. 
Via The Motley Fool
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
The company is retaining the rights to specific over-the-counter drugs in some markets. 
Via Investor's Business Daily
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by  
Via Benzinga
Could Viatris Stock Help You Become a Millionaire?
Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment? 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to... 
Via Benzinga
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7." 
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
These stocks offer some mouth-watering payouts. 
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Viatris, GSK, and Organon are all trading at less than 7 times earnings. 
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
CVS just fired a shot across Viatris' bow. 
Via The Motley Fool
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
There are a few complicating factors that mean the generic form of the drug might not be a slam dunk. 
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.